0001209191-21-045591.txt : 20210706
0001209191-21-045591.hdr.sgml : 20210706
20210706173544
ACCESSION NUMBER: 0001209191-21-045591
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20210701
FILED AS OF DATE: 20210706
DATE AS OF CHANGE: 20210706
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ostertag Eric
CENTRAL INDEX KEY: 0001765987
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39376
FILM NUMBER: 211075288
MAIL ADDRESS:
STREET 1: C/O POSEIDA THERAPEUTICS, INC.
STREET 2: 4242 CAMPUS POINT COURT, SUITE 700
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Poseida Therapeutics, Inc.
CENTRAL INDEX KEY: 0001661460
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 472846548
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9390 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-779-3100
MAIL ADDRESS:
STREET 1: 9390 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-07-01
0
0001661460
Poseida Therapeutics, Inc.
PSTX
0001765987
Ostertag Eric
C/O POSEIDA THERAPEUTICS, INC.
9390 TOWNE CENTRE DRIVE, STE 200
SAN DIEGO
CA
92121
1
1
1
0
Chief Executive Officer
Common Stock
2021-07-01
4
S
0
10729
9.77
D
3770413
I
See footnote
Common Stock
2021-07-02
4
S
0
104
9.65
D
3770309
I
See footnote
Common Stock
2021-07-02
4
S
0
14266
8.90
D
3756043
I
See footnote
Common Stock
2021-07-01
4
S
0
9834
9.77
D
3460124
I
See footnote
Common Stock
2021-07-02
4
S
0
96
9.65
D
3460028
I
See footnote
Common Stock
2021-07-02
4
S
0
13076
8.90
D
3446952
I
See footnote
Common Stock
542985
D
Common Stock
629194
I
See footnote
Common Stock
961445
I
See footnote
Common Stock
200696
I
See footnote
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2020.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.58 to $10.17 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held in the name of the Eric Ostertag Living Trust dated March 30, 2016, of which the reporting person is the sole trustee.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.64 to $9.66 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the
range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.61 to $9.51 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the
range set forth in this footnote.
The shares are held in the name of Titan, LLC, which is owned by the Ostertag Descendents' Trust, of which the reporting person's minor daughter is the sole beneficiary. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
The shares are held in the name of Twin Prime Investments, an entity wholly owned by the reporting person.
The shares are held in the name of the Ostertag Family Trust dated March 30, 2016, of which the reporting person is a trustee.
The shares are held in the name of Transposagen Biopharmaceuticals, Inc., of which Dr. Ostertag is a majority stockholder.
/s/ Harry J. Leonhardt, Attorney-in-Fact
2021-07-06
EX-24.4_997946
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby constitutes and appoints
each of Mark J. Gergen, Johanna M. Mylet and Harry J. Leonhardt of Poseida
Therapeutics, Inc. (the "Company"), signing individually, the undersigned's true
and lawful attorney-in fact and agent to:
(1) execute for and on behalf of the undersigned, an officer, director or holder
of 10% of more of a registered class of securities of the Company, Forms 3, 4
and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934,
as amended (the "Exchange Act") and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to complete and execute such Form 3, 4 or 5,
complete and execute any amendment or amendments thereto, and timely file such
forms or amendments with the United States Securities and Exchange Commission
and any stock exchange or similar authority; and
(3) take any other action of any nature whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that each of the foregoing
attorneys-in-fact, in serving in such capacity at the request of the
undersigned, is not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the foregoing attorney-in-fact or (c) until such attorney-in-fact
shall no longer be employed by the Company.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 18th day of June, 2021.
/s/ Eric Ostertag